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In the physiological process of fibrinolysis, the enzymes now considered to be 
of prime  importance  are  plasminogen  and  tissue-type  plasminogen  activator 
(t-PA) 1 (1).  Recently,  evidence has  been  presented  (1)  for  the  occurrence in 
plasma  of a  fast-acting  PA  inhibitor.  Together  with  the  fast-acting  plasmin 
inhibitor  a2-antiplasmin,  the  PA-inhibitor  determines  to  a  great  extent  the 
expression of the fibrinolytic potential of plasma (1). After the discovery of the 
PA-inhibitor,  it  has  rapidly  become  clear  that  the  plasma  levels  of the  PA- 
inhibitor are highly variable, and can be subject to rapid changes, e.g. following 
trauma, surgery, or infection. 
During a  study of factors affecting PA-inhibitor levels in rats, we noted that 
LPS  greatly  increased  plasma  PA-inhibitor  concentrations.  In  this  paper,  we 
describe the effects of LPS and of IL-I  (a postulated mediator of LPS-induced 
effects) on PA-inhibitor  levels in  rat plasma,  and  on PA-inhibitor synthesis by 
human endothelial ceils, as these cells are known to secrete PA-inhibitor in vitro 
(2). 
Materials and Methods 
Rats.  Male Wistar rats (200-250 g  body weight) were obtained from the Centraal 
Proefdierenbedrijf TNO  (Zeist,  The  Netherlands).  All  animal  experiments were per- 
formed under Nembutal anaesthesia (60 mg/kg i.p.). 
Cultured Human Endothelial Cells.  Human endothelial cells were isolated from umbil- 
ical cord veins and grown to confluency on fibronectin-coated dishes as described (3). 
Subcultures were obtained by trypsin/EDTA at a split ratio of 3:1. 
Lipopolysaccharide.  Escherichia  coli LPS (serotype O128:B12), prepared by the phenolic 
extraction procedure, was obtained from Sigma Chemical Co. (St.  Louis, MO). A stock 
solution of 1 mg/ml in sterile saline was stored at -20°C. 
Human IL-1.  Human IL-I was supplied by Genzyme (Haverhill, United Kingdom) as 
a  solution of 100  U/ml  in  5%  FCS  in  RPMI  1640.  The IL-1  had  been prepared by 
immunoadsorbtion chromatography from Staphylococcus albus-stimulated human mono- 
cytes. 
Recombinant Murine IL-1.  rIL-1, lot 14827-48, 3 ×  10  ~ U/ml, was a gift from Dr. P. 
T. Lomedico (Hoffman-La Roche, Inc., Nutley, N  J) (4). Polymyxin B, cycloheximide, and 
actinomycin D were obtained from Sigma Chemical Co.; saline and human serum albumin 
from CLB (Amsterdam, the  Netherlands).  Following the procedure prescribed by the 
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manufacturer (Kabi  Vitrum,  Stockholm, Sweden)  all  materials  used  were  tested  for 
endotoxin contamination by the Coatest Endotoxin kit, and found to be endotoxin-free 
(detection limit 5 pg/ml), except for rlL-1 (see Results). 
Animal Experiments.  LPS was injected i.v. in a volume of 2 ml/kg. Control rats received 
saline only. At the times specified, blood was obtained by aortic puncture and andcoagu- 
lated with 0.1  volume of trisodium citrate (0.13  M). Platelet-free plasma was prepared 
and stored at -70°C. 
Human IL-I (diluted to  10 U/ml, using a  1% solution of human serum albumin in 
saline) was infused for 60 min through the vein of the penis at a dosage of 50 U/kg body 
weight, rIL-1 (diluted to 1,000 U/mi with albumin/saline) was given similarly at a dose of 
5,000  U/kg. Blood samples were obtained from a cannula in the carotid artery before 
starting of the infusion, and after 1, 2, 3, and 4 h. Controls for human IL-1 received the 
same volume of 1% human albumin in saline.  Controls for rlL-I received heated rlL-1 
(100°C for 60 min). 
Cell Culture Experiments.  Confluent cultures were used at second or third passage, and 
were always refed the day before the experiment. Conditioned media were obtained by 
incubating cells at 37 °C for various times (up to 24 h) with culture medium, or (after two 
washes with serum-free medium) with serum-free medium containing 0.3 mg/ml human 
serum albumin. Conditioned media were centrifuged to remove cells and cell debris, and 
stored at -20°C. Protein was determined according to Wang and Smith (5), using BSA 
as a standard. 
PA-inhibitor  Assay.  The fast-acting inhibitor of t-PA was determined by titration of 
samples with increasing amounts of t-PA, followed by spectrophotometric measurement 
of the residual t-PA activity, as described by Verheijen et al. (6). The PA-inhibitor activity 
of the sample was then determined by graphical extrapolation (6, 7). The PA-inhibitor 
activity is expressed in IU of t-PA inhibited. 
Stability of PA-inhibitor.  Samples were incubated at  37°C  for  1-24  h,  followed by 
determination of residual PA-inhibitor activity (8). 
Results 
Rat  plasma,  like  human  plasma,  contained  t-PA  inhibitor,  as  detected  by 
titration with t-PA.  In plasma  from control  rats,  the PA-inhibitor activity was 
21.6 +  2.5 IU/ml (mean _+SD; n --- 27). In parallel experiments, the PA-inhibitor 
activity of pooled human plasma was  13.3  +  1.4  IU/ml (n =  20).  Injection of 
LPS into rats resulted in a  rapid increase in plasma PA-inhibitor activity. At an 
LPS dosage  of 10  #g/kg (Fig.  1 a),  a  significant increase,  up  to  320%  of the 
control value, was already seen after 2  h, while maximally increased values of 
~ 1,500%  were reached 4 h  after injection. At later time intervals, PA-inhibitor 
levels gradually returned to normal. A second injection of LPS (10 #g/kg), 24 h 
after a first dose of 10 #g/kg, again resulted in increased PA-inhibitor levels 4 h 
later, although the effect of the second injection was slight diminished (Fig.  1 a). 
Significantly increased  PA-inhibitor  concentrations  were  found (at  4  h) after 
injecting  LPS  at  a  dose  of as  little  as  10  ng]kg,  increasing  responses  being 
obtained up to dosages of 1 mg/kg (Fig.  1 b). Rats, bled 4 h  after injection with 
LPS (10 ug/kg), did not differ from control rats with regard to plasma plasmin- 
ogen (92  +  11%  of controls; mean +SD; n  =  5), fibrinogen (97  +  8%) and o~- 
antiplasmin (98 _+ 10%) concentrations. 
As endothelial cells are known (2, 3, 9) to secrete a  PA-inhibitor in vitro, we 
subsequently studied  the  effect of LPS on  PA-inhibitor synthesis by cultured 
human endothelial cells. As shown in Fig. 2a and Table I, LPS dose-dependently 
increased PA-inhibitor synthesis. Cycloheximide (1 gg/ml) suppressed both basal 
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FIGURE  1.  PA-inhibitor activity in rat plasma after i.v. injection of E. coli LPS. Data shown 
in a are means 4-SD (It) (n = 4-7) of PA-inhibitor activity in plasma from rats bled at various 
times after injecting LPS (I0 ttg/kg). Also shown is the effect of two injections of LPS (both 
10 ~g/kg), at 0 and at 24 h; plasma was obtained at 28 h (0) (n = 4). b shows means +SD (n = 
4) of PA-inhibitor activity in rat plasma 4 h after injecting increasing amounts of LPS. In both 
graphs, the 100% value equals 21.6 4- 2.5 IU/ml. 
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FIGURE 2.  PA-inhibitor activity in (secondary) endothelial cell-conditioned medium after 
incubation for various periods of time in the presence of LPS (0-10 #g/ml) (a), or of human 
IL-I (0-5 U/ml) (b). In this representative experiment (compare Table I), the culture medium 
contained 20% (vol/vol) of serum. 
of incubation.  Actinomycin  D  (40  ng/ml) suppressed the  LPS-induced increase 
in inhibitor synthesis (LPS,  192  _+ 61%,  LPS plus actinomycin D,  106  +  21%  of 
control values), showing that the effect of LPS required de novo mRNA  synthesis. 
No  increased  inhibitor  synthesis  was  seen  when,  before  being  added  to  cells, 
polymyxin B,  an antibiotic that inactivates LPS,  was mixed with  LPS  (data not 
shown). EMEIS  AND  KOOISTRA 
TABLE  I 
Effect of LPS or Human IL-1 on PA-inhibitor Activity in Conditioned Media from 
Cultured Human Endothelial Cells 
1263 
Stimulant added 
PA-inhibitor activity (IU/mg cell protein)* 
Serum-free medium  Serum-free medium  Serum-containing 
(8 h)  (24 h)  medium (24 h) 
No addition 
LPS (10 #g/ml) 
Human IL-1 (5 U/ml) 
32.5 ± 7.3 (4)  40.2 ± 20.6 (5)  87.4 ± 55.4 (5) 
64.8 ± 33.7 (4)  125.8 ± 45.2 (6)  398.0 ± 67.9 (7) 
124.9 ± 9.7 (3)  193.0 ± 61.0 (3)  366.7 ± 23.3 (7) 
* Mean ± SD. Number of cultures (n) is shown in parentheses. 
TABLE  II 
Effect of Infusion with IL-1 on PA-inhibitor Activity in Rat Plasma 
PA-inhibitor activity (% of time 0 value) 
Time (h)  Human IL-1  rlL-1  Human IL-1  rIL-1  (controls)  (controls) 
0  100 ±  12  100 +  15  100 ±  14  100 ± 7 
1  94  _  6  104  +  6  ND  ND 
2  104 ±  13  104 ±  16  171 + 30 *~  118 + 6 
3  132 + 23  105 ± 8  161 ± 25*  128 __. 24 
4  139 ±  16"*  108 ± 5  163 ±  16"  158 ± 52 
Rats were infused  for 1 h with human IL-I (50 U/kg) or with rIL-I (5,000  U/kg), 
and blood samples were obtained at hourly intervals thereafter. Data shown are means 
+SD of three rats in each group. Time 0 values were 18.1 + 4.0 IU/ml for the six 
animals treated with IL-I, and 18.0 ± 3.1 IU/ml for the six control animals. 
* Significantly different from time 0 value. 
* Significantly different from control value at that time (student's t-test; p < 0.05). 
Also,  increased  inhibitor  synthesis  could  be  induced  in  cultured  endothelial 
cells by human  IL-I. The  dose dependency and the time course of the effect of 
human  IL-1  is  shown  in  Fig.  2b.  As  was  the  case  for  LPS,  the  human  IL-1- 
induced effect was suppressed  by cycloheximide and actinomycin D  (human  IL- 
l  at  5  U/mi,  321  _+  14%  of control values;  human  IL-1  plus cycloheximide, 48 
_+  18%;  human  IL-1 plus actinomycin  D,  106 +_  14%).  Heating the IL-1  for  15 
min at  80°C  completely  undid  its effect,  while  the  same  procedure  would  not 
affect  the  LPS-induced  increase  in  PA-inhibitor  synthesis  (data  not  shown). 
Similar results were obtained using rlL-1, although at least 20 times higher riL- 
l  concentrations  were  required  to obtain  a  similar  effect.  The  effect  of rIL-1 
was  again  abolished  by  heating,  but  was  insensitive  to  polymyxin  B  (data  not 
shown).  The  LPS- and  IL-l-induced  increases  in  inhibitor  level  could  not  be 
ascribed  to a  decreased  release  of t-PA  by endothelial  cells,  as  determined  by 
enzyme immunoassay of t-PA antigen (T.  Kooistra, unpublished observations). 
Infusion  of IL-1  (both  human  and  mouse  recombinant)  into rats  resulted  in 
small  but  significant  increases  in  plasma  PA-inhibitor  activity  (Table  II).  The 
slow increase  of PA-inhibitor  in rats treated  with heated  rIL-1  can probably be 
ascribed  to the  endotoxin  content  of the infusate  (60 pg/ml).  Also,  in  this  case 
rIL-1 proved to be less active than human  IL-1. 
Both the endothelial  PA-inhibitor and the induced PA-inhibitor in rat plasma 1264  ENDOTOXIN,  INTERLEUKIN  1,  AND  FIBRINOLYTIC  INHIBITOR 
were unstable during incubation at 37°C. The in vitro half-life at 37°C was 2.0 
+  0.3 h  for the rat plasma inhibitor, and 2.3  +_ 0.3  h  (mean +SD; n  =  6) for 
endothelial inhibitor. 
Discussion 
This study defines LPS and IL-1  as potent inducers of PA-inhibitor, both in 
vivo in rats and in human endothelial cell cultures. That the inhibitory activity 
measured by the titration assay is indeed due to PA-inhibition and not to plasmin 
inhibition has been demonstrated before (6, 9).  Moreover, plasma levels of the 
major plasmin inhibitor a2-antiplasmin were unchanged in LPS-treated rats.  A 
similar effect of LPS  on  PA-inhibitor activity has  recently been described in 
rabbits in vivo and in cultured human endothelial cells by Colucci et al.  (10). 
Whether the effects observed in vivo are due to increased PA-inhibitor synthesis 
by endothelial cells remains speculative, since the cellular origin of plasma PA- 
inhibitor is still unknown. However, LPS and IL-1 did not increase PA-inhibitor 
synthesis by the human hepatoma cell line Hep G2  or by primary monolayer 
cultures of human  hepatocytes (our unpublished  observations),  but  then  the 
induced plasma PA-inhibitor and the endothelial cell-derived PA-inhibitor are 
closely related with regard to molecular weight (7),  inhibition constant (Ki; 2-5 
pM [7]), immunochemical characteristics (8), and instability at 37 ° C. Therefore 
it is likely that these PA-inhibitors are homologous proteins, and that the increase 
in plasma inhibitor is due to increased synthesis by endothelial cells. 
The induction of PA-inhibitor synthesis in cultured endothelial cells strongly 
resembles the induction of procoagulant activity in those cells, also induced by 
LPS (11) and by IL-1 (12). Although endothelial cells in vitro can synthesize IL- 
l  (13) and IL-1  synthesis is increased by LPS (14), it remains to be established 
whether LPS acts by way of increased IL-1 synthesis in endothelial cells. 
Murine IL-1  proved less  potent in our experiments than human monocyte- 
derived IL-1, both in the rat in vivo and in the human cell culture system. As 
the rI L-1 used (4) is an IL-1 a (15), and human monocytes contain predominantly 
mRNA for IL-1/3 (15), the data suggest that IL-1/3 might be a better inducer of 
PA-inhibitor than IL-la.  Verification of this suggestion will,  however, require 
further experiments. 
Summary 
Human  IL-1,  recombinant murine  IL-1  and E.  coli  LPS  were found to  be 
potent inducers of plasminogen activator (PA)-inhibitor activity, both in vivo, in 
rats, as well as in cultured human endothelial cells. 
In  vivo,  LPS  rapidly  and  dose-dependently (0.01-1,000  /+g/kg)  increased 
plasma PA-inhibitor activity. Infusion of IL-1  into rats resulted in a  small but 
significant increase in PA-inhibitor activity in rat plasma. 
Likewise, in cultured human umbilical vein endothelial cells,  LPS and IL-1 
induced increased synthesis of PA-inhibitor. 
We  suggest  that  the  induced rat  plasma  inhibitor  might  be  of endothelial 
origin. EMEIS AND  KOOISTRA  1265 
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